Browse NLRC5

Summary
SymbolNLRC5
NameNLR family, CARD domain containing 5
Aliases NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location16q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm
Domain PF12799 Leucine Rich repeats (2 copies)
PF13516 Leucine Rich repeat
Function

Probable regulator of the NF-kappa-B and type I interferon signaling pathways. May also regulate the type II interferon signaling pathway. Plays a role in homeostatic control of innate immunity and in antiviral defense mechanisms.

> Gene Ontology
 
Biological Process GO:0001818 negative regulation of cytokine production
GO:0001959 regulation of cytokine-mediated signaling pathway
GO:0001960 negative regulation of cytokine-mediated signaling pathway
GO:0001961 positive regulation of cytokine-mediated signaling pathway
GO:0002683 negative regulation of immune system process
GO:0009615 response to virus
GO:0031348 negative regulation of defense response
GO:0031349 positive regulation of defense response
GO:0032088 negative regulation of NF-kappaB transcription factor activity
GO:0032479 regulation of type I interferon production
GO:0032480 negative regulation of type I interferon production
GO:0032606 type I interferon production
GO:0034340 response to type I interferon
GO:0034341 response to interferon-gamma
GO:0043433 negative regulation of sequence-specific DNA binding transcription factor activity
GO:0045088 regulation of innate immune response
GO:0045089 positive regulation of innate immune response
GO:0045341 MHC class I biosynthetic process
GO:0045343 regulation of MHC class I biosynthetic process
GO:0045345 positive regulation of MHC class I biosynthetic process
GO:0045824 negative regulation of innate immune response
GO:0050777 negative regulation of immune response
GO:0051090 regulation of sequence-specific DNA binding transcription factor activity
GO:0051607 defense response to virus
GO:0060330 regulation of response to interferon-gamma
GO:0060332 positive regulation of response to interferon-gamma
GO:0060333 interferon-gamma-mediated signaling pathway
GO:0060334 regulation of interferon-gamma-mediated signaling pathway
GO:0060335 positive regulation of interferon-gamma-mediated signaling pathway
GO:0060337 type I interferon signaling pathway
GO:0060338 regulation of type I interferon-mediated signaling pathway
GO:0060339 negative regulation of type I interferon-mediated signaling pathway
GO:0060340 positive regulation of type I interferon-mediated signaling pathway
GO:0060759 regulation of response to cytokine stimulus
GO:0060760 positive regulation of response to cytokine stimulus
GO:0060761 negative regulation of response to cytokine stimulus
GO:0071346 cellular response to interferon-gamma
GO:0071357 cellular response to type I interferon
GO:0098542 defense response to other organism
Molecular Function GO:0000979 RNA polymerase II core promoter sequence-specific DNA binding
GO:0001046 core promoter sequence-specific DNA binding
GO:0001047 core promoter binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-936440: Negative regulators of RIG-I/MDA5 signaling
R-HSA-168928: RIG-I/MDA5 mediated induction of IFN-alpha/beta pathways
Summary
SymbolNLRC5
NameNLR family, CARD domain containing 5
Aliases NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location16q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between NLRC5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between NLRC5 and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
27162338Pan-CancerPromote immunity (infiltration)Strikingly, NLRC5 expression was significantly associated with the activation of CD8(+) cytotoxic T cells and patient survival in multiple cancer types.
Summary
SymbolNLRC5
NameNLR family, CARD domain containing 5
Aliases NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location16q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of NLRC5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell logFC: 1.48; FDR: 0.000150 Sensitive to T cell-mediated killing
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NS NA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolNLRC5
NameNLR family, CARD domain containing 5
Aliases NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location16q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of NLRC5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.2180.521
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.4590.746
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.0530.953
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.350.415
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.2570.921
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.4770.894
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.5810.213
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.0540.463
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.0490.976
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.3710.347
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.5650.484
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.1180.466
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of NLRC5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.107.10.452
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277311.18.22.90.699
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 01407.1-7.11
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275911.18.52.60.702
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21179.55.93.61
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.79.1-1.41
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.112.5-1.41
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59022.2-22.20.505
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.37.4-2.11
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22139.17.71.41
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161407.1-7.10.467
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 111307.7-7.71
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 51208.3-8.31
Summary
SymbolNLRC5
NameNLR family, CARD domain containing 5
Aliases NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location16q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of NLRC5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolNLRC5
NameNLR family, CARD domain containing 5
Aliases NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location16q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of NLRC5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by NLRC5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolNLRC5
NameNLR family, CARD domain containing 5
Aliases NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location16q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of NLRC5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolNLRC5
NameNLR family, CARD domain containing 5
Aliases NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location16q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of NLRC5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolNLRC5
NameNLR family, CARD domain containing 5
Aliases NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location16q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between NLRC5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolNLRC5
NameNLR family, CARD domain containing 5
Aliases NOD27; CLR16.1; FLJ21709; nucleotide-binding oligomerization domain, leucine rich repeat and CARD domain con ......
Chromosomal Location16q13
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting NLRC5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.